According to filings with the U.S. Securities and Exchange Commission, Kolon TissueGene is raising $30,000,024.00 in new funding. Sources indicate that as part of senior management Chief Executive Officer, Moon Noh played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Kolon TissueGene
At Kolon TissueGene, our mission is to provide safe and effective therapies to patients by reducing pain and improving function associated with various orthopedic diseases and degenerative disorders. Kolon TissueGene has developed its unique technology platform in cell and gene therapy over the past 20 years through the development of Invossa. After many years, when cell and gene therapy was looked at questionably or even skeptically by the market at large, Kolon TissueGene and other companies – including large pharma – are now successfully utilizing this technology to develop drugs, and even gain market approval. As time goes on, we expect more and more companies will rapidly move into this innovative and promising space within drug development. Our extensive experience and knowledge in cell and gene therapy will be the basis for expanding Kolon TissueGenes pipeline into other indications while securing our position as a leader in advanced cell therapies.

To learn more about Kolon TissueGene, visit http://www.tissuegene.com/

Contact:
Moon Noh, Chief Executive Officer
301-921-6000

SOURCE: http://www.intelligence360.io
Copyright (c) 2023 SI360 Inc. All rights reserved.